Side effect management and medication guidance of Asnib/Asiminib

Asciminib (trade name: Scemblix) is an oral inhibitor targeting BCR-ABL1 and is a new allosteric inhibitor of STI-571 (STAMP), mainly used for patients with chronic myelogenous leukemia (CML), especially those who are resistant or intolerant to first-line or multi-line TKIs such as imatinib, dasatinib or nilotinib. Different from traditional ATP competitive tyrosine kinase inhibitors, asinib specifically inhibits BCR-ABL1 activity through allosteric binding sites, reducing the risk of drug-resistant mutations, thereby achieving long-term disease control. Due to its high target specificity, the side effect spectrum is relatively mild, but safety management and tolerability monitoring still need to be paid attention to in clinical use.

Asnib has been shown to be well tolerated in clinical studies, but it still has certain side effects. The most common hematological adverse reactions include neutropenia, thrombocytopenia and anemia, especially in patients with multi-line TKI resistance. Common non-hematological adverse reactions include diarrhea, nausea, fatigue, musculoskeletal pain, abnormal liver function, and elevated blood lipids. Most side effects are mild to moderate and can be alleviated by symptomatic treatment, dose adjustment, or short-term discontinuation. A small number of patients may develop cardiovascular events, such as QTc prolongation or arrhythmias, so increased monitoring is required in patients with a history of heart disease or concomitant medications.

For hematological adverse reactions, routine blood tests should be monitored regularly, especially during the initial stage of treatment or during dose adjustment. When a significant decrease in neutrophils or platelets occurs, the dose can be adjusted or the drug temporarily discontinued under the guidance of a doctor, and growth factor support or blood transfusion therapy can be used if necessary. For abnormal liver function, liver enzyme and bilirubin levels should be checked regularly. If there is a significant increase, the drug needs to be discontinued or the dose reduced, and other potential hepatotoxic factors should be investigated. Gastrointestinal symptoms such as diarrhea and nausea can be improved through dietary adjustments, symptomatic treatment with medications, and divided medication. Dyslipidemia should be managed with a combination of lifestyle intervention and pharmacotherapy.

Asnib should be taken orally in strict accordance with the doctor's prescription. It is generally recommended to take it at a fixed time every day and avoid taking it with high-fat meals to reduce absorption differences. Patients should truthfully report all concomitant medications, including herbal medicines, supplements and over-the-counter drugs, to their doctor while taking the medication to avoid drug interactions. During initial use or dose adjustment, it is recommended to closely follow up blood routine, liver and kidney function and electrocardiogram to detect and deal with adverse reactions in a timely manner. If serious side effects occur, such as persistent high fever, severe infection, obvious bleeding or abnormal heart rhythm, you should contact your doctor immediately and do not stop taking the medicine or adjust the dose on your own.

Elderly patients and patients with multiple chronic diseases or previous cardiovascular diseases should use asinib with caution as the risk of side effects is higher. During long-term medication, regular reexaminations should be maintained to evaluate efficacy and tolerance, and the dose should be reasonably adjusted based on hematological indicators and imaging results. Patients should record daily symptom changes and medication usage to facilitate doctors' judgment of drug tolerance and efficacy. If there are signs of drug resistance or disease progression, you should communicate with your doctor in time and consider combining other treatments or adjusting the plan.

In home management, patients should maintain a healthy routine, a balanced diet and moderate exercise to enhance physical strength and immunity. Pay attention to avoid contact with sources of infection, and strengthen protection during cold or flu season. Patients can prepare a "medication diary" to record daily medication, blood routine results and changes in adverse reactions, so that doctors can evaluate the treatment effect during follow-up. When minor side effects occur, diet adjustment, rest or drug treatment can be used to ensure that the efficacy of the drug is not affected.

In general, asinib is a highly selective BCR-ABL inhibitor, suitable for CML patients who are resistant or intolerant to other TKI. Common side effects can be effectively controlled through standardized monitoring, dose adjustment and symptomatic treatment. Patients should strictly follow the doctor's instructions, review on time, record changes in symptoms, and seek medical treatment promptly if serious adverse reactions occur. Through close cooperation between doctors and patients, scientific management and long-term follow-up, the efficacy of asinib can be maximized while ensuring safety, and a long-lasting and effective disease control plan can be provided for CML patients.

Reference materials:https://www.drugs.com/